{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-24-000033","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.599447+00:00","generated_at":"2026-05-31T11:51:35.177967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Assertio Q2 net product sales $30.7M, GAAP net loss $3.7M; reiterates FY guidance","bullets":["Net product sales $30.7M vs $40.1M in Q2 2023; GAAP net loss $0.04/share vs income $0.13/share.","Rolvedon net sales $15.1M, up from $14.5M QoQ; Indocin $6.9M, down from $8.7M due to generic competition.","Adjusted EBITDA $5.0M vs $24.8M in Q2 2023; cash from operations $7.4M.","Cash & short-term investments $88.4M, up from $80.7M; debt $40.0M in 6.5% convertible notes due 2027.","FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-24-000033","json":"https://secwatch.observer/filing/0001808665-24-000033.json","markdown":"https://secwatch.observer/filing/0001808665-24-000033.md","text":"https://secwatch.observer/filing/0001808665-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866524000033/0001808665-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866524000033/asrt-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:51:35.177967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}